I have to agree with YakYak. I've been using the NxStage System One and PureFlow for over four years. It has made a tremendous difference in my life compared to in-center dialysis. The flexibility of the treatments, the benefits of frequent treatments, and the portability of the dialysis machine make this a great option. I am noticeably healthier with NxStage treatment than I was with in-center treatment.
The only caveat is that the patient has to have a willing dialysis partner and both patient and partner need to be willing to take personal responsibility for their care. Some dialysis patients don't want to be involved, and just want to go to the clinic and get treatment without having to think about anything. Those patients are not good candidates for this system. Of the 400,000 or so dialysis patients receiving treatment, fewer than 6,000 of those patients are doing home hemodialysis. That's lots of room for growth, but the patient has to be the right type for home treatment to be considered.
I do wish that I had bought this stock when I started using the system, back in 2009. The gains would have been substantial! I do think that there is room for this stock to go up, especially since Medicare won't be forcing the higher cuts, at least for a while.